Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (211)

2024

  1. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer

    Cell Death Discovery, Vol. 10, Núm. 1

2023

  1. Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (npj Breast Cancer, (2021), 7, 1, (1), 10.1038/s41523-020-00208-2)

    npj Breast Cancer

  2. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies

    Cancers, Vol. 15, Núm. 18

  3. Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

    ACS Applied Materials and Interfaces, Vol. 15, Núm. 32, pp. 38323-38334

  4. Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

  5. Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells

    Cell Death and Differentiation, Vol. 30, Núm. 5, pp. 1366-1381

  6. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  7. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer

    International journal of molecular sciences, Vol. 24, Núm. 4

  8. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors

    International Journal of Molecular Sciences, Vol. 24, Núm. 14

  9. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400

  10. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

    Cancers, Vol. 15, Núm. 7

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

  2. Role of germline variants in the metastasis of breast carcinomas

    Oncotarget, Vol. 13, Núm. 1, pp. 843-862

  3. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

  4. miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

    Cancer Communications

2021

  1. Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3 VNTR polymorphisms and gene co-expression

    npj Breast Cancer, Vol. 7, Núm. 1

  2. Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

    ESMO Open, Vol. 6, Núm. 1

  3. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

  4. Identification of a two-microrna signature in plasma as a novel biomarker for very early diagnosis of breast cancer

    Cancers, Vol. 13, Núm. 11

  5. Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool

    ACS Sensors, Vol. 6, Núm. 3, pp. 1022-1029